Search the GHTC website

Global health R&D delivers for Louisiana

US government investment in global health R&D has delivered

$324.6 million
to Louisiana research institutions
4,400+ new jobs
for Louisiana
Louisiana's top USG-funded global health R&D institutions

Louisiana's top USG-funded global health R&D institutions

Tulane University of Louisiana
$266.3 million
Louisiana State University and A&M College (including Health Sciences Center and the Pennington Biomedical Research Center)
$36.7 million
National Hansen's Disease Program
$10.1 million
University of Louisiana at Lafayette
$9.2 million
NanoPin Technologies
$2.1 million
Loyola University New Orleans
$265 thousand
Southern University at Shreveport
$11 thousand

Louisiana's top areas of global health R&D by USG funding

Arenaviral hemorrhagic fevers (including Lassa fever)
Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Multi-disease/health area R&D
Reproductive health
Salmonella infections
Global health R&D at work in Louisiana

Tulane University researchers are developing a vaccine to prevent Chagas disease, a parasitic illness that can eventually lead to heart damage and failure if left untreated. While the disease mostly impacts individuals living in Central and South America, with 6 million people infected worldwide, it is estimated that up to 300,000 people are living with this neglected disease in the United States. The kissing bugs that transmit the disease have been found in 27 states, including Louisiana—putting more than half of the country at risk. There is currently no approved vaccine for Chagas disease, underscoring the importance of continued vaccine development efforts.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIH/FIC/Richard Lord